Invention Grant
US08236304B2 Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity
有权
使用PD-L3蛋白和PD-L3特异性抗体或抗体片段调节CD4 +和CD8 + T细胞免疫
- Patent Title: Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity
- Patent Title (中): 使用PD-L3蛋白和PD-L3特异性抗体或抗体片段调节CD4 +和CD8 + T细胞免疫
-
Application No.: US11912397Application Date: 2006-04-24
-
Publication No.: US08236304B2Publication Date: 2012-08-07
- Inventor: Randolph J. Noelle , Li-Fan Lu , Sergio Quezada , David Gondek
- Applicant: Randolph J. Noelle , Li-Fan Lu , Sergio Quezada , David Gondek
- Applicant Address: US NH Hanover
- Assignee: Trustees of Dartmouth College
- Current Assignee: Trustees of Dartmouth College
- Current Assignee Address: US NH Hanover
- Agency: Hunton & Williams LLP
- International Application: PCT/US2006/015239 WO 20060424
- International Announcement: WO2006/116181 WO 20061102
- Main IPC: A61K39/395
- IPC: A61K39/395
Abstract:
The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed.
Public/Granted literature
Information query
